drugset / Trial / NCT06913218
A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC
NaSequentialOpen-labelTreatment
Summary
To explore safety and efficacy of neoantigen personalized mRNA vaccines AK154 monotherapy or in combination with AK104/AK112 and sequential mFOLFIRINOX regime in Resected PDAC
Timeline
- Start
- 2025-07-22
- Primary completion
- 2028-02-23
- Completion
- 2028-11-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AK154 | Messenger RNA (mRNA) | — | — |
| Subject | Cadonilimab | Monoclonal antibody | — | — |
| Subject | Irinotecan | Small molecule | — | — |
| Subject | Ivonescimab | Monoclonal antibody | — | — |
| Subject | Leucovorin | Small molecule | — | — |
| Subject | Oxaliplatin | Small molecule | — | — |
| Subject | fluorouracil | Small molecule | — | — |